🚨Trade Alert 🚨 PRPH

🚨Trade Alert 🚨 PRPH͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ This Little-Known Biotech Company Has Been Seeing its Shares Surge…. Greetings Investors, Investors are always curious to find out which company will become the next biotech giant. Revenues, management, offerings, analyst coverage... all these things are important when considering how well a company may do in the long term. One biotech company on the NASDAQ has been gaining attention in recent weeks and hits all the markers above! Revenues have seen a colossal explosion of 1,100% since 2019, the company’s CEO is well esteemed and recently recognized as a top health innovator by Inc. Magazine, and BULLish ratings are piling up! Hurry and add ProPhase Labs, Inc. to your radar. [www.ProPhaseLabs.com]( ProPhase Labs, Inc. NASDAQ: PRPH In recent days PRPH shares have exploded from around $7.55 to over $9 - a move that may be in response to all of the positive announcements that have been released. AND… Diamond Equity Research has initiated a 32-page report on the company with a hefty $20 valuation! The report includes detailed information on the ProPhase’s business model, services, industry, valuation, management, and risks. You can read the report here: [( Remarkable snippets from the report include these investment highlights: - Diagnostics Business Enabling Pivot Toward Niche and Emerging Business Segments: ProPhase's strategic evolution from a predominantly diagnostics-centric company to a multifaceted healthcare organization is underscored by its ability to capitalize on the success and cash generation of its diagnostics division. By investing in and growing healthcare companies such as genomics and biopharma, the company expands its market presence and fosters revenue diversification. The company's management is ambitiously striving to transform ProPhase Labs into an all-encompassing healthcare powerhouse, with diagnostics and genomics pinpointing disease origins, contract manufacturing delivering top-tier production capabilities, and the biopharma division driving the development of cutting-edge therapies and treatments. - Solid Financial Performance Showcasing Substantial Progress: The company reported strong growth across all its major business divisions for the year ended 2022. In 2022, ProPhase Labs reported revenue of $122.64 million, a significant increase from the $79.04 million recorded in 2021. This translates to a year-over-year (y-o-y) growth rate of 55.16%. Revenues have increased over 1,000% in the last few years: If this wasn’t enough,[WSJ]( has a $15 price target on the stock and [NASDAQ]( has a “STRONG BUY” rating… Insider ownership stands at 22% as optimism grows for the company’s long-term outlook. With CEO Ted Karkus leading the way, PRPH could be on its way to becoming another biotech darling! Last month Karkus was named one of [Inc Magazine’s]( 10 Most Innovative Healthcare Leaders to Watch in 21023! Under his guidance, ProPhase Labs has rapidly evolved from a legacy over-the-counter healthcare products and supplements company to a diversified, next-generation biotech, genomics and diagnostics company with multiple new products and subsidiaries. In the article, Mr. Karkus was highlighted for his leadership stewarding ProPhase Labs through the coronavirus pandemic, and his efforts to bring cutting-edge technologies and therapies to the healthcare industry through subsidiaries ProPhase Diagnostics, ProPhase BioPharma and Nebula Genomics. Mr. Karkus was also instrumental in the company’s quick pivot into the COVID-19 testing business at the onset of the pandemic, generating over $200 million in revenue over the past few years and fueling the company’s long-term growth and diversification strategies. He wants to turn PRPH into a multi-billion dollar company! This is the man who transformed ID Biomedical’s strategy and valuation from $25 million to [$1.4 billion sale]( to GlaxoSmithKline. For PRPH he restructured the go-to-market strategy for the flagship product Cold-EEZE and significantly grew revenues, ultimately selling it for [$50 million to Mylan.]( The full article can be written here: [( Company Overview: ProPhase Labs, Inc. (NASDAQ: PRPH), based in Long Island, NY, USA, has been working on developing and providing varied healthcare products and services to the broad public and other institutions. Founded in 1989, the company offers a vast array of clinical diagnostics and testing services at its Clinical Laboratory Improvement Amendments (CLIA) certified laboratories, including polymerase chain reaction (PCR) testing for SARS-CoV-2 (COVID-19), Influenza A, Influenza B and Respiratory syncytial virus (RSV). It also possesses advanced technologies for genomics sequencing and testing; and specializes in the development, manufacturing, and marketing of over-the-counter (OTC) health and wellness products. Cold-EEZE, its flagship product, sold to Mylan Pharma in 2017, helped bring in liquidity amounting to $50 million, and the company still continues to contract-manufacture the lozenges in its Pharmaloz (PMI) manufacturing facility. It distributes its products to major retailers across the United States, including Walmart, Walgreens, CVS Health Corporation, and Amazon, among others. A Growth-Oriented Portfolio Nebula Genomics - The pioneers and leader in Whole Genome Sequencing with one of the most accurate, highest quality and price competitive solutions on the market. Offering deep insights for consumers, universities, and the healthcare industry with best-in-class tools and interpretation capabilities. Nebula was founded by world-renowned geneticist George Church. He is active with the company and sits on the company’s Advisory Board. Nebula was the first company to bring the cost of sequencing a human genome below $300 and became one of the largest direct-to-consumer Whole Genome Sequencing companies! In fact, the company “cracked the code” on how to bring the Whole Genome Sequencing to mass market consumers! ProPhase’s goal is to dramatically increase Nebula’s sales by decreasing price, decreasing turnaround times and increasing distribution to both businesses and consumers, including universities conducting genetic research. Announced in March 2023 that Nebula has introduced its lowest ever standard price of $249 for its direct-to-consumer Whole Genome Sequencing DNA test! ProPhase Diagnostics - State-of-the-art diagnostic laboratory services with a complete CLIA clinical lab offering, to include Chemistry, Immunoassay, Upper Respiratory, Hematology, Hemostasis and Urinalysis. Delivered millions of highly accurate Upper Respiratory laboratory diagnostics, including PCR, antigen and flu tests in our state-of-the-art CLIA laboratories. ProPhase Biopharma - Developing groundbreaking compounds and products. Licensing and developing with the goal of commercializing Equivir (dietary supplement) and Equivir G (Rx), two broad based anti-virals, as well as Linebacker LB-1 and LB-2, two small molecule PIM kinase inhibitors for cancer treatment. Linebacker is a small molecule, multi-kinase inhibitor that is being developed as a potential mono-therapy and co-therapy option for hard-to-treat cancers. Originally viewed as a co-therapy, pre-clinical data generated has given PBIO reason to believe that LB-1 will also be very effective as a mono-therapy. In line with [impressive results]( revealed recently, Linebacker-1 has demonstrated strong preclinical potential in a number of difficult diseases, including tough-to-treat lung and gastric cancers. Pharmaloz - 30+ years of OTC manufacturing services and consumer healthcare product development from non-GMO, Organic and/or Natural-based cough drops and lozenges for over-the-counter drugs to dietary supplement products. TK Supplements - Clinically-backed consumer products promoting better health, energy, and sexual vitality available online, Walmart, Walgreens, CVS, Rite-Aid and more. The BE-Smart Test PRPH has acquired the world-wide exclusive rights to the BE-Smart Esophageal Pre-Cancer diagnostic screening test and related intellectual property assets. The BE-Smart Esophageal Pre-Cancer Diagnostic Screening test is aimed at early detection of esophageal cancer. It has already been tested by an independent test lab, mProbe, Inc. on over 200 human samples and has shown an area under curve of greater than 99% in distinguishing highly impactful histologic classifications. ProPhase Labs plans to pursue initial commercialization of the BE-Smart test as an LDT (Laboratory Developed Test) and RUO (Research Use Only). The goal of widespread adoption of the BE-Smart diagnostic test would allow health care providers to initiate potentially lifesaving early treatment processes such as an ablation procedure to remove the precancerous cells and could also significantly reduce unnecessary endoscopies. The number of endoscopies related to gastrointestinal disease, in the United States was 54.1 million in 2019 and is expected to to around 94.7 million by 2060.]( “With partners like mProbe and Dr. Hartley of the Mayo Clinic, we are optimistic that we can meet our commercialization goals for this potentially life-saving test. We are also in preliminary discussions to license, develop and ultimately commercialize our BE-Smart test in other countries.” – CEO Ted Karkus. In Summary… ProPhase Labs, Inc. (NASDAQ: PRPH) is firing on all cylinders to become one of the most notable biotech, genomics and diagnostics firms on Wall Street… The genomics business and esophageal pre-cancer test operate in promising markets with billion-dollar opportunities. The management remains strongly optimistic about its genomics business and expects over 100% growth in 2023! “With Nebula Genomics, and the potential game changer diagnostics and therapeutics we are developing, including our BE-Smart Esophageal Cancer Test, Linebacker cancer compounds, and broad based Equivir anti-virals, as well as our new fully diversified, state-of-the-art clinical lab and genomics testing lab, I promise that we are just getting started and that there is a lot more to come!” – CEO Ted Karkus The company is anticipated to release Q1 financial results on 5/11 so keep an eye out! With Several Lucrative and Innovative Divisions, ProPhase Labs, Inc. (NASDAQ: PRPH) is Starting to Capture Major Attention and Could See Considerable Growth Ahead! Start your research! Copyright 2023 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in PRPH. We have been currently compensated up to Twenty Five Thousand Dollars Cash ($25,000) via bank wire transfer from a third-party IA Media, LLC for a 1 Day Marketing Program regarding PRPH with a start date of 5/05/2023. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. No longer want to receive these emails? [Unsubscribe](. Small Caps Daily 1334 Northampton St Easton, PA 18042